NCCN Clinical Practice Guidelines in Oncology. Hodgkin Lymphoma. Version 2.2013.
NCCN Clinical Practice Guidelines in Oncology. Anal Carcinoma. Version 1.2014.
NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers. Version 2.2013.
U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:627–637.
U.S. Preventive Services Task Force. Screening for Testicular Cancer: Recommendation Statement. Rockville, MD: Agency for Healthcare Research and Quality; 2004.
Eichenauer DA, Engert A, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011; 22 Suppl 6: vi55-58.
HIV/AIDS and Cancer
Pinzone MR, Fiorica F, Di Rosa M, Malaguarnera G, Malaguarnera L, Cacopardo B, Zanghì G, Nunnari G. Non-AIDS-defining cancers among HIV-infected people. Eur Rev Med Pharmacol Sci. 2012 Oct;16(10):1377-88.
Althoff K, Wyatt C, Gibert C, et al. HIV-infected adults are at greater risk for myocardial infarction (MI), end-stage renal disease (ESRD), and non-AIDS-defining cancers, but events occur at similar ages compared to HIV–uninfected adults. Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections; March 3-6, 2013; Atlanta, Georgia. Abstract 59.
Signe W Worm, Mark Bower, Peter Reiss, Fabrice Bonnet, Matthew Law, Gerd Fätkenheuer, Antonella d’Arminio Monforte, Donald I Abrams, Andrew Grulich, Eric Fontas, Ole Kirk, Hansjakob Furrer,Stephane De Wit, Andrew Phillips, Jens D Lundgren, Caroline A Sabin and for the D:A:D Study Group. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. BMC Infectious Diseases 2013, 13:471.
Shiels M, Pfeiffer R, Gail M, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103:753–762.
Engels EA, Brock MV, Chen J et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24: 1383-1388.
ENGELS EA, PFEIFFER RM, GOEDERT JJ, VIRGO P, MCNEEL TS, SCOPPA SM, BIGGAR RJ. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20: 1645-1654.
Helleberg M, Afzal S, Kronborg G, et al. Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis 2013; 56:727–734.
POWLES T, ROBINSON D, STEBBING J, SHAMASH J, NELSON M, GAZZARD B, MANDELIA S, MØLLER H, BOWER M. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27: 884-890.
HERNDIER BG, SANCHEZ HC, CHANG KL, CHEN YY, WEISS LM. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin’s disease. Am J Pathol 1993; 142: 1073-1079.
Tirelli U, Errante D, Dolcetti R, al. e. Hodgkin's disease and HIV infection: Clinicopathologic and virologic features of 114 patients from the Italian cooperative group on AIDS and tumors. J Clin Oncol 1995; 13: 1758-1767.
Glaser SL, Clarke CA, Gulley ML et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer 2003; 98: 300-309.
Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-1636.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27–34.
Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54:1026–1034.
Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2012; 118:6226–6233.
BERRETTA M, GARLASSI E, CACOPARDO B, CAPPELLANI A, GUARALDI G, COCCHI S, DE PAOLI P, LLESHI A, IZZI I, TORRESIN A, DI GANGI P, PIETRANGELO A, FERRARI M, BEARZ A, BERRETTA S, NASTI G, DI BENEDETTO F, BALESTRERI L, TIRELLI U, VENTURA P. Hepatocellular Carcinoma in HIV-Infected Patients: Check Early, Treat Hard. Oncologist 2011; 16: 1258-1269.
Powles T, Macdonald D, Nelson M, Stebbing J. Hepatocellular cancer in HIV-infected individuals: tomorrow's problem? Expert Rev Anticancer Ther 2006; 6: 1553-1558.
Puoti M, Bruno R, Soriano V et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18: 2285-2293.
Goedert JJ, Schairer C, McNeel TS, et al. Risk of breast, ovary, and uterine corpus cancers among 85.268 women with AIDS. Br J Cancer 2006; 95:642–648.
Dauby N, De Wit S, Delforge M, et al. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. J Int AIDS Soc 2011; 14:16.
Shiels MS, Goedert JJ, Moore RD, et al. Reduced risk of prostate cancer in U.S. men with AIDS. Cancer Epidemiol Biomarkers Prev 2010; 19:2910–2915.
Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285: 1736-1745.
Schroder FH, Hugosson J, Roobol MJ, et al., for the ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320–1328.
ARV Therapy and cancer
Bower M, Powles T, Nelson M et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. Aids 2003; 17: 371-375.
GUIGUET M, BOUE F, CADRANEL J, LANG JM, ROSENTHAL E, COSTAGLIOLA D. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 2009; 10:1152-1159.
D’JAEN G, PANTANOWITZ L, BOWER M, BUSKIN S, NEIL N, GRECO EM, COOLEY TP, HENRY D, STEM J, DEZUBE BJ, STEBBING J, ABOULAFIA DM. Human immunodeficiency virus– associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010; 11: 396-404.
Cancer treatments and HIV
Montoto S, Shaw K, Okosun J et al. HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. J Clin Oncol 2012.
Jacobson CA, Abramson JS. HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART. Adv Hematol 2012; 2012: 507257.
XICOY B, RIBERA JM, MIRALLES P, BERENGUER J, RUBIO R, MAHILLO B, VALENCIA ME, ABELLA E, LÓPEZGUILLERMO A, SUREDA A, MORGADES M, NAVARRO JT, H; GESIDA GROUP; GELCAB GROUP. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin’s lymphoma. Haematologica 2007; 92: 191-198.
LEVINE AM, LI P, CHEUNG T, TULPULE A, VON ROENN J, NATHWANI BN, RATNER L. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin’s disease: a prospective, multiinstitutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24: 444-450.
Alfa-Wali M, Allen-Mersh T, Antoniou A et al. Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. Ann Oncol 2012; 23: 141-147.
Vibert E, Duclos-Vallee JC, Ghigna MR et al. Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology 2011; 53: 475-482.
Berretta M, Di Benedetto F, Dal Maso L et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anticancer Drugs 2013; 24: 212-218.
Cancer and HIV-uninfected patients
Eich HT, Diehl V, Gorgen H et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199-4206.
Hoskin PJ, Lowry L, Horwich A et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009; 27: 5390-5396.
Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000 Mar 16;342(11):792-800.
Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008 Apr 23;299(16):1914-1921.
Faivre C, Rougier P, Ducreux M, Mitry E, Lusinchi A, Lasser P, Elias D, Eschwege F. 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer. Bull Cancer. 1999 Oct;86(10):861-865.
Lee SJ, Boscardin WJ, Stijacic-Cenzer I, et al. Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. BMJ 2013; 346:e8441.
Heijnsdijk EA, Wever EM, Auvinen A, et al. Quality-of-life effects of prostatespecific antigen screening. N Engl J Med 2012; 367:595–605.